The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Open accessAbstract
Proteasomes are large, multisubunit proteolytic complexes presenting multiple targets for therapeutic intervention. The 26S proteasome consists of a 20S proteolytic core and one or two 19S regulatory particles. The 20S core contains three types of active sites. Many structurally diverse inhibitors of these active sites, both natural product and synthetic, have been discovered in the last two decades. One, bortezomib, is used clinically for treatment of multiple myeloma, mantle cell lymphoma, and acute allograft rejection. Five more recently developed proteasome inhibitors are in trials for treatment of myeloma and other cancers. Proteasome inhibitors also have activity in animal models of autoimmune and inflammatory diseases, reperfusion injury, promote bone and hair growth, and can potentially be used as anti-infectives. In addition, inhibitors of ATPases and deubiquitinases of 19S regulatory particles have been discovered in the last decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Activators and Target Genes of Rel/NF-кB Transcription Factors: From Bench to Bedside
Loop, T., & Pahl, H. L. (2003) · Nuclear Factor кB · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,169
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES
Coux, O., Tanaka, K., & Goldberg, A. L. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.004101 · Cited by 2,487
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Finley, D. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081507.101607 · Cited by 1,764
Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
How Proteolysis Drives the Cell Cycle
King, R. W., Deshaies, R. J., Peters, J.-M., & Kirschner, M. W. (1996) · Science · doi:10.1126/science.274.5293.1652 · Cited by 1,273
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
Self-citationProteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Lee, K. P., & Boise, L. H. (2006) · Blood · doi:10.1182/blood-2005-08-3531 · Cited by 1,143
Role of Rpn11 Metalloprotease in Deubiquitination and Degradation by the 26 S Proteasome
Verma, R., Aravind, L., Oania, R., McDonald, W. H., Yates, J. R., Koonin, E. V., & Deshaies, R. J. (2002) · Science · doi:10.1126/science.1075898 · Cited by 1,000
Cancer prevention by tea: animal studies, molecular mechanisms and human relevance
Yang, C. S., Wang, X., Lu, G., & Picinich, S. C. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2641 · Cited by 995
DEGRADATION OF CELL PROTEINS AND THE GENERATION OF MHC CLASS I-PRESENTED PEPTIDES
Rock, K. L., & Goldberg, A. L. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.739 · Cited by 921
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Meng, L., Mohan, R., Kwok, B. H. B., Elofsson, M., Sin, N., & Crews, C. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10403 · Cited by 920
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Enhancement of proteasome activity by a small-molecule inhibitor of USP14
Lee, B.-H., Lee, M. J., Park, S., Oh, D.-C., Elsasser, S., Chen, P.-C., Gartner, C., Dimova, N., Hanna, J., Gygi, S. P., et al. (2010) · Nature · doi:10.1038/nature09299 · Cited by 893
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 678
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637 · cited 1×
“These compounds induce apoptosis in proliferating cells, but whether apoptosis is due to proteasome inhibition is not clear as these compounds may have dozens if not hundreds of other cellular targets (Liby et al., 2007; Yang et al., 2009).”
BackgroundMuchamuel, T., Basler, M., Aujay, M. A., Suzuki, E., Kalim, K. W., Lauer, C., Sylvain, C., Ring, E. R., Shields, J., Jiang, J., et al. (2009) · Nature Medicine · doi:10.1038/nm.1978 · Cited by 599
Neubert, K., Meister, S., Moser, K., Weisel, F., Maseda, D., Amann, K., Wiethe, C., Winkler, T. H., Kalden, J. R., Manz, R. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1763 · Cited by 584
Regulation of CD8 + T Cell Development by Thymus-Specific Proteasomes
Murata, S., Sasaki, K., Kishimoto, T., Niwa, S.-I., Hayashi, H., Takahama, Y., & Tanaka, K. (2007) · Science · doi:10.1126/science.1141915 · Cited by 580
Heinemeyer, W., Fischer, M., Krimmer, T., Stachon, U., & Wolf, D. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25200 · Cited by 519
Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors
Palmer, J. T., Rasnick, D., Klaus, J. L., & Bromme, D. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00017a002 · Cited by 508
Ester Bond-containing Tea Polyphenols Potently Inhibit Proteasome Activity in Vitro and in Vivo
Nam, S., Smith, D. M., & Dou, Q. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004209200 · Cited by 504
Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Kupperman, E., Lee, E. C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2766 · Cited by 499
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
D'Arcy, P., Brnjic, S., Olofsson, M. H., Fryknäs, M., Lindsten, K., De Cesare, M., Perego, P., Sadeghi, B., Hassan, M., Larsson, R., et al. (2011) · Nature Medicine · doi:10.1038/nm.2536 · Cited by 492
Groll, M., Berkers, C. R., Ploegh, H. L., & Ovaa, H. (2006) · Structure · doi:10.1016/j.str.2005.11.019 · Cited by 473
The proteasome inhibitor PS-341 in cancer therapy.
Teicher, B. A., Ara, G., Herbst, R. S., Palombella, V. J., & Adams, J. (1999) · PubMed · Cited by 472
LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D. S., Goloubeva, O. G., Pien, C. S., Adams, J., et al. (2002) · PubMed · Cited by 450
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Aghajanian, C. A., Soignet, S. L., Dizon, D. S., Pien, C. S., Adams, J., Elliott, P. J., Sabbatini, P. J., Miller, V. A., Hensley, M. L., Pezzulli, S., et al. (2002) · PubMed · Cited by 447
Bogyo, M., McMaster, J. S., Gaczynska, M., Tortorella, D., Goldberg, A. L., & Ploegh, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6629 · Cited by 447
Kisselev, A. F., Callard, A., & Goldberg, A. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509043200 · Cited by 416
Self-citationExtensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition
Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2258 · Cited by 410
Köhler, A., Cascio, P., Leggett, D. S., Woo, K. M., Goldberg, A. L., & Finley, D. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00274-x · Cited by 409
Arastu-Kapur, S., Anderl, J. L., Kraus, M., Parlati, F., Shenk, K. D., Lee, S. J., Muchamuel, T., Bennett, M. K., Driessen, C., Ball, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1950 · Cited by 408
Chen, P., & Hochstrasser, M. (1996) · Cell · doi:10.1016/s0092-8674(00)80171-3 · Cited by 404
Proteasome and peptidase function in MHC-class-I-mediated antigen presentation
Kloetzel, P.-M., & Ossendorp, F. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2003.11.004 · Cited by 393
Craiu, A., Gaczynska, M., Akopian, T., Gramm, C. F., Fenteany, G., Goldberg, A. L., & Rock, K. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.20.13437 · Cited by 382
Wang, Q., Mora-Jensen, H., Weniger, M. A., Perez-Galan, P., Wolford, C., Hai, T., Ron, D., Chen, W., Trenkle, W., Wiestner, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807611106 · Cited by 343
Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells
Qin, J.-Z., Ziffra, J., Stennett, L., Bodner, B., Bonish, B. K., Chaturvedi, V., Bennett, F., Pollock, P. M., Trent, J. M., Hendrix, M. J. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0676 · Cited by 336
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
Garrett, I. R., Chen, D., Gutierrez, G., Zhao, M., Escobedo, A., Rossini, G., Harris, S. E., Gallwitz, W., Kim, K. B., Hu, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16198 · Cited by 328
Parlati, F., Lee, S. J., Aujay, M., Suzuki, E., Levitsky, K., Lorens, J. B., Micklem, D. R., Ruurs, P., Sylvain, C., Lu, Y., et al. (2009) · Blood · doi:10.1182/blood-2009-05-223677 · Cited by 324
Chauhan, D., Tian, Z., Zhou, B., Kuhn, D., Orlowski, R., Raje, N., Richardson, P., & Anderson, K. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0476 · Cited by 316
Groll, M., Huber, R., & Potts, B. C. M. (2006) · Journal of the American Chemical Society · doi:10.1021/ja058320b · Cited by 312
A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism
Groll, M., Schellenberg, B., Bachmann, A. S., Archer, C. R., Huber, R., Powell, T. K., Lindow, S., Kaiser, M., & Dudler, R. (2008) · Nature · doi:10.1038/nature06782 · Cited by 308
Tsubuki, S., Saito, Y., Tomioka, M., Ito, H., & Kawashima, S. (1996) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021280 · Cited by 306
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. M. (2000) · Journal of the American Chemical Society · doi:10.1021/ja993588m · Cited by 304
Arendt, C. S., & Hochstrasser, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7156 · Cited by 302
O'Connor, O. A., Stewart, A. K., Vallone, M., Molineaux, C. J., Kunkel, L. A., Gerecitano, J. F., & Orlowski, R. Z. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0822 · Cited by 295
Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis
Palombella, V. J., Conner, E. M., Fuseler, J. W., Destree, A., Davis, J. M., Laroux, F. S., Wolf, R. E., Huang, J., Brand, S., Elliott, P. J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15671 · Cited by 287
André, P., Groettrup, M., Klenerman, P., de Giuli, R., Booth, B. L., Cerundolo, V., Bonneville, M., Jotereau, F., Zinkernagel, R. M., & Lotteau, V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13120 · Cited by 279
Zhou, H.-J., Aujay, M. A., Bennett, M. K., Dajee, M., Demo, S. D., Fang, Y., Ho, M. N., Jiang, J., Kirk, C. J., Laidig, G. J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801329v · Cited by 272
Bianchi, G., Oliva, L., Cascio, P., Pengo, N., Fontana, F., Cerruti, F., Orsi, A., Pasqualetto, E., Mezghrani, A., Calbi, V., et al. (2009) · Blood · doi:10.1182/blood-2008-08-172734 · Cited by 267
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib
Berkers, C. R., Verdoes, M., Lichtman, E., Fiebiger, E., Kessler, B. M., Anderson, K. C., Ploegh, H. L., Ovaa, H., & Galardy, P. J. (2005) · Nature Methods · doi:10.1038/nmeth759 · Cited by 262
Gandotra, S., Schnappinger, D., Monteleone, M., Hillen, W., & Ehrt, S. (2007) · Nature Medicine · doi:10.1038/nm1683 · Cited by 254
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. (2000) · Worldwide Protein Data Bank · doi:10.2210/pdb1g65/pdb · Cited by 253
Piva, R., Ruggeri, B., Williams, M., Costa, G., Tamagno, I., Ferrero, D., Giai, V., Coscia, M., Peola, S., Massaia, M., et al. (2008) · Blood · doi:10.1182/blood-2007-07-100651 · Cited by 252
Ichikawa, H. T., Conley, T., Muchamuel, T., Jiang, J., Lee, S., Owen, T., Barnard, J., Nevarez, S., Goldman, B. I., Kirk, C. J., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33333 · Cited by 244
C. Potts, B., X. Albitar, M., C. Anderson, K., Baritaki, S., Berkers, C., Bonavida, B., Chandra, J., Chauhan, D., C. Cusack, J., Fenical, W., et al. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519716 · Cited by 243
Trimming of Ubiquitin Chains by Proteasome-associated Deubiquitinating Enzymes
Lee, M. J., Lee, B.-H., Hanna, J., King, R. W., & Finley, D. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r110.003871 · Cited by 238
Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome
Basler, M., Dajee, M., Moll, C., Groettrup, M., & Kirk, C. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903182 · Cited by 236
A transgenic mouse model of the ubiquitin/proteasome system
Lindsten, K., Menéndez-Benito, V., Masucci, M. G., & Dantuma, N. P. (2003) · Nature Biotechnology · doi:10.1038/nbt851 · Cited by 234
Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin in Cultured Cells
Dick, L. R., Cruikshank, A. A., Destree, A. T., Grenier, L., McCormack, T. A., Melandri, F. D., Nunes, S. L., Palombella, V. J., Parent, L. A., Plamondon, L., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.182 · Cited by 228
Fernández, Y., Verhaegen, M., Miller, T. P., Rush, J. L., Steiner, P., Opipari, A. W., Lowe, S. W., & Soengas, M. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0686 · Cited by 222
Proteasome inhibition: a new anti-inflammatory strategy
Elliott, P. J., Zollner, T. M., & Boehncke, W.-H. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0422-2 · Cited by 221
Inhibitors selective for mycobacterial versus human proteasomes
Lin, G., Li, D., de Carvalho, L. P. S., Deng, H., Tao, H., Vogt, G., Wu, K., Schneider, J., Chidawanyika, T., Warren, J. D., et al. (2009) · Nature · doi:10.1038/nature08357 · Cited by 208
Kuhn, D. J., Hunsucker, S. A., Chen, Q., Voorhees, P. M., Orlowski, M., & Orlowski, R. Z. (2009) · Blood · doi:10.1182/blood-2008-07-171637 · Cited by 207
A Fluorescent Broad-Spectrum Proteasome Inhibitor for Labeling Proteasomes In Vitro and In Vivo
Verdoes, M., Florea, B. I., Menendez-Benito, V., Maynard, C. J., Witte, M. D., van der Linden, W. A., van den Nieuwendijk, A. M. C. H., Hofmann, T., Berkers, C. R., van Leeuwen, F. W. B., et al. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.013 · Cited by 200
Self-citationResponse to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
Zangari, M., Esseltine, D., Lee, C., Barlogie, B., Elice, F., Burns, M. J., Kang, S., Yaccoby, S., Najarian, K., Richardson, P., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05733.x · Cited by 199
Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach
Groll, M., & Huber, R. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.025 · Cited by 193
Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain
Verma, R., Peters, N. R., D'Onofrio, M., Tochtrop, G. P., Sakamoto, K. M., Varadan, R., Zhang, M., Coffino, P., Fushman, D., Deshaies, R. J., et al. (2004) · Science · doi:10.1126/science.1100946 · Cited by 193
Figueiredo‐Pereira, M. E., Berg, K. A., & Wilk, S. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63041578.x · Cited by 181
Nazif, T., & Bogyo, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061028898 · Cited by 179
Groll, M., Koguchi, Y., Huber, R., & Kohno, J. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4869 · Cited by 176
Schmidt, N., Gonzalez, E., Visekruna, A., Kühl, A. A., Loddenkemper, C., Mollenkopf, H., Kaufmann, S. H. E., Steinhoff, U., & Joeris, T. (2010) · Gut · doi:10.1136/gut.2009.203554 · Cited by 166
Britton, M., Lucas, M. M., Downey, S. L., Screen, M., Pletnev, A. A., Verdoes, M., Tokhunts, R. A., Amir, O., Goddard, A. L., Pelphrey, P. M., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.11.015 · Cited by 165
Self-citationAbrogation of Anti-HLA Antibodies via Proteasome Inhibition
Trivedi, H. L., Terasaki, P. I., Feroz, A., Everly, M. J., Vanikar, A. V., Shankar, V., Trivedi, V. B., Kaneku, H., Idica, A. K., Modi, P. R., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a4b91b · Cited by 164
Eponemycin exerts its antitumor effect through the inhibition of proteasome function.
Meng, L., Kwok, B. H. B., Sin, N., & Crews, C. M. (1999) · PubMed · Cited by 155
Progressively impaired proteasomal capacity during terminal plasma cell differentiation
Cenci, S., Mezghrani, A., Cascio, P., Bianchi, G., Cerruti, F., Fra, A., Lelouard, H., Masciarelli, S., Mattioli, L., Oliva, L., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601009 · Cited by 155
Nickeleit, I., Zender, S., Sasse, F., Geffers, R., Brandes, G., Sörensen, I., Steinmetz, H., Kubicka, S., Carlomagno, T., Menche, D., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.016 · Cited by 154
Elofsson, M., Splittgerber, U., Myung, J., Mohan, R., & Crews, C. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80128-8 · Cited by 153
Blackburn, C., Gigstad, K. M., Hales, P., Garcia, K., Jones, M. D., Bruzzese, F. J., Barrett, C., Liu, J. X., Soucy, T. A., Sappal, D. S., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100383 · Cited by 152
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Altun, M., Galardy, P., Shringarpure, R., Hideshima, T., LeBlanc, R., Anderson, K., Ploegh, H., & Kessler, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0506 · Cited by 149
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib
Fennell, D. A., Chacko, A., & Mutti, L. (2007) · Oncogene · doi:10.1038/sj.onc.1210744 · Cited by 146
Granot, Z., Kobiler, O., Melamed‐Book, N., Eimerl, S., Bahat, A., Lü, B., Braun, S., Maurizi, M. R., Suzuki, C. K., Oppenheim, A. B., et al. (2007) · Molecular Endocrinology · doi:10.1210/me.2005-0458 · Cited by 141
Gomez, A. M., Vrolix, K., Martínez‐Martínez, P., Molenaar, P. C., Phernambucq, M., van der Esch, E., Duimel, H., Verheyen, F., Voll, R. E., Manz, R. A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002539 · Cited by 140
PROTEASOME INHIBITION IN MULTIPLE MYELOMA: Therapeutic Implication
Chauhan, D., Hideshima, T., & Anderson, K. C. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100037 · Cited by 135
Lack of Proteasome Active Site Allostery as Revealed by Subunit-Specific Inhibitors
Myung, J., Kim, K. B., Lindsten, K., Dantuma, N. P., & Crews, C. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00188-5 · Cited by 123
Tsubuki, S., Kawasaki, H., Saito, Y., Miyashita, N., Inomata, M., & Kawashima, S. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2378 · Cited by 120
LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology
Ho, Y. K., Bargagna‐Mohan, P., Wehenkel, M., Mohan, R., & Kim, K. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.03.008 · Cited by 117
Gaczynska, M. E., Osmulski, P. A., Gao, Y., Post, M. J., & Simons, M. (2003) · Biochemistry · doi:10.1021/bi034784f · Cited by 113
Proteasome inhibition: A novel mechanism to combat asthma☆☆☆
Elliott, P. J., Pien, C. S., McCormack, T. A., Chapman, I. D., & Adams, J. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70369-6 · Cited by 111
Mirabella, A., Pletnev, A. A., Downey-Kopyscinski, S. L., Florea, B. I., Shabaneh, T. B., Britton, M., Verdoes, M., Filippov, D. V., Overkleeft, H. S., & Kisselev, A. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.02.015 · Cited by 107
Self-citationTiedemann, R. E., Schmidt, J. E., Keats, J. J., Shi, C.-X., Zhu, Y. X., Palmer, S. E., Mao, X., Schimmer, A. D., & Stewart, A. K. (2008) · Blood · doi:10.1182/blood-2008-09-179796 · Cited by 107
Proteasome Inhibition by Fellutamide B Induces Nerve Growth Factor Synthesis
Hines, J. F., Groll, M., Fahnestock, M. L., & Crews, C. M. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.03.020 · Cited by 106
Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib
Chen, S., Blank, J. L., Peters, T., Liu, X. J., Rappoli, D. M., Pickard, M. D., Menon, S., Yu, J., Driscoll, D. L., Lingaraj, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4428 · Cited by 106
The Proteasome Inhibitor Epoxomicin Has Potent Plasmodium falciparum Gametocytocidal Activity
Czesny, B., Goshu, S., Cook, J. L., & Williamson, K. C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00088-09 · Cited by 98
Hamilton, A. L., Eder, J. P., Pavlick, A. C., Clark, J. W., Liebes, L., García‐Carbonero, R., Chachoua, A., Ryan, D. P., Soma, V., Farrell, K., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.136 · Cited by 97
WILLIAMS, A., DAVE, J., & Tortella, F. C. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.03.018 · Cited by 91
Groll, M., Nazif, T. M., Huber, R., & Bogyo, M. S. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00144-8 · Cited by 84
Effect of Noncompetitive Proteasome Inhibition on Bortezomib Resistance
Li, X., Wood, T. E., Sprangers, R., Jansen, G., Franke, N. E., Mao, X., Wang, X., Zhang, Y., Verbrugge, S. E., Adomat, H. H., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq198 · Cited by 80
Asai, A., Tsujita, T., Sharma, S. V., Yamashita, Y., Akinaga, S., Funakoshi, M., Kobayashi, H., & Mizukami, T. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.08.035 · Cited by 77
Fissolo, N., Kraus, M., Reich, M., Ayturan, M., Overkleeft, H. S., Driessen, C., & Weissert, R. (2008) · European Journal of Immunology · doi:10.1002/eji.200838413 · Cited by 71
Self-citationBifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes
Loidl, G., Groll, M., Musiol, H., Ditzel, L., Huber, R., & Moroder, L. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80036-2 · Cited by 68
Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer
Molineaux, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0853 · Cited by 68
Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors
Screen, M., Britton, M., Downey-Kopyscinski, S. L., Verdoes, M., Voges, M. J. E. E. E., Blom, A. E. M., Geurink, P. P., Risseeuw, M., Florea, B. I., van der Linden, W. A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160606 · Cited by 61
Self-citationProteostenosis and plasma cell pathophysiology
Cenci, S., van Anken, E., & Sitia, R. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.11.004 · Cited by 59
Manam, R. R., McArthur, K., Chao, T., Weiss, J., Ali, J. A., Palombella, V. J., Groll, M., Lloyd, G. K., Palladino, M. A., Neuteboom, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800548b · Cited by 57
Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells
Kazi, A., Lawrence, H. R., Guida, W. C., McLaughlin, M. L., Springett, G. M., Berndt, N., Yip, R., & Sebti, S. M. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8798 · Cited by 53
A panel of subunit-selective activity-based proteasome probes
Verdoes, M., Willems, L. I., van der Linden, W. A., Duivenvoorden, B. A., van der Marel, G. A., Florea, B. I., Kisselev, A. F., & Overkleeft, H. S. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c001036g · Cited by 52
Self-citationProteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Groll, M., & Potts, B. C. M. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611798281320 · Cited by 51
Early clinical experience with the novel proteasome inhibitor PS–519
Shah, I. M., Lees, K. R., Pien, C. S., & Elliott, P. J. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01638.x · Cited by 51
Lim, H., Cai, D., Archer, C. T., & Kodadek, T. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja075469+ · Cited by 43
Frase, H., Hudak, J. E., & Lee, I. (2006) · Biochemistry · doi:10.1021/bi060542e · Cited by 43
Momose, I., Sekizawa, R., Hirosawa, S., Ikeda, D., NAGANAWA, H., IINUMA, H., & TAKEUCHI, T. (2001) · The Journal of Antibiotics · doi:10.7164/antibiotics.54.1004 · Cited by 36
Graewert, M. A., Gallastegui, N., Stein, M., Schmidt, B., Kloetzel, P., Huber, R., & Groll, M. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201005488 · Cited by 35
Geurink, P. P., Liu, N., Spaans, M. P., Downey-Kopyscinski, S. L., van den Nieuwendijk, A. M. C. H., van der Marel, G. A., Kisselev, A. F., Florea, B. I., & Overkleeft, H. S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9015685 · Cited by 33
Self-citationvan der Linden, W. A., Willems, L. I., Shabaneh, T. B., Li, N., Ruben, M., Florea, B. I., van der MAREL, G. A., Kaiser, M., Kisselev, A. F., & Overkleeft, H. S. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c1ob06554h · Cited by 33
Self-citationThe Development and Pharmacology of Proteasome Inhibitors for the Management and Treatment of Cancer
Ruggeri, B., Miknyoczki, S. J., Dorsey, B. D., & Hui, A. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57003-7 · Cited by 32
Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors
Steverding, D., Spackman, R. W., Royle, H. J., & Glenn, R. J. (2004) · Parasitology Research · doi:10.1007/s00436-004-1253-y · Cited by 23
Roth, P., Kissel, M., Herrmann, C., Eisele, G., Leban, J. J., Weller, M., & Schmidt, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0548 · Cited by 20
Active-Site-Directed Chemical Tools for Profiling Mitochondrial Lon Protease
Fishovitz, J., Li, M., Frase, H., Hudak, J. E., Craig, S. N., Ko, K. S., Berdis, A. J., Suzuki, C. K., & Lee, I. (2011) · ACS Chemical Biology · doi:10.1021/cb100408w · Cited by 17
Bortezomib’s Scientific Origins and Its Tortuous Path to the Clinic
Goldberg, A. L. (2010) · Springer eBooks · doi:10.1007/978-3-7643-8948-2_1 · Cited by 12
Targeting Tumor Proteasome with Traditional Chinese Medicine
Yang, H., Liu, J., & Dou, Q. P. (2010) · Current Drug Discovery Technologies · doi:10.2174/157016310791162785 · Cited by 11
Cited by
Targeting the unfolded protein response in disease
Hetz, C., Chevet, E., & Harding, H. P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3976 · Cited by 910
Emerging Targets in Photopharmacology
Lerch, M. M., Hansen, M. J., van Dam, G. M., Szymanski, W., & Feringa, B. L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601931 · Cited by 675
Mitochondrial metabolism promotes adaptation to proteotoxic stress
Tsvetkov, P., Detappe, A., Cai, K., Keys, H. R., Brune, Z., Ying, W., Thiru, P., Reidy, M., Kugener, G., Rossen, J., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0291-9 · Cited by 645
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
Zolotovskaia, M. A., Sorokin, M. I., Emelianova, A. A., Borisov, N. M., Kuzmin, D. V., Borger, P., Garazha, A. V., & Buzdin, A. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00001 · Cited by 531
Metadata
- Authors
- Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 19
- Issue
- 1
- Pages
- 99-115
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W1999042605
- Cited by
- 527
- References
- 132
- FWCI
- 22.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.